Literature DB >> 33687564

The mechanisms and reversal strategies of tumor radioresistance in esophageal squamous cell carcinoma.

Hongfang Zhang1,2, Jingxing Si3, Jing Yue1, Shenglin Ma4,5,6.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of most lethal malignancies with high aggressive potential in the world. Radiotherapy is used as one curative treatment modality for ESCC patients. Due to radioresistance, the 5-year survival rates of patients after radiotherapy is less than 20%. Tumor radioresistance is very complex and heterogeneous. Cancer-associated fibroblasts (CAFs), as one major component of tumor microenvironment (TME), play critical roles in regulating tumor radioresponse through multiple mechanisms and are increasingly considered as important anti-cancer targets. Cancer stemness, which renders cancer cells to be extremely resistant to conventional therapies, is involved in ESCC radioresistance due to the activation of Wnt/β-catenin, Notch, Hedgehog and Hippo (HH) pathways, or the induction of epithelial-mesenchymal transition (EMT), hypoxia and autophagy. Non-protein-coding RNAs (ncRNAs), which account for more than 90% of the genome, are involved in esophageal cancer initiation and progression through regulating the activation or inactivation of downstream signaling pathways and the expressions of target genes. Herein, we mainly reviewed the role of CAFs, cancer stemness, non-coding RNAs as well as others in the development of radioresistance and clarify the involved mechanisms. Furthermore, we summarized the potential strategies which were reported to reverse radioresistance in ESCC. Together, this review gives a systematic coverage of radioresistance mechanisms and reversal strategies and contributes to better understanding of tumor radioresistance for the exploitation of novel intervention strategies in ESCC.

Entities:  

Keywords:  ESCC; Mechanisms; Molecular targets; Radioresistance; Reversal strategies

Mesh:

Substances:

Year:  2021        PMID: 33687564     DOI: 10.1007/s00432-020-03493-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  55 in total

1.  HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression.

Authors:  Qinghua Dong; Sherven Sharma; Hai Liu; Long Chen; Benxing Gu; Xiaonan Sun; Guanyu Wang
Journal:  Toxicol Lett       Date:  2014-01-03       Impact factor: 4.372

2.  The role of DNA methyltransferase 3b in esophageal squamous cell carcinoma.

Authors:  Miao-Fen Chen; Ming-Shian Lu; Paul-Yang Lin; Ping-Tsung Chen; Wen-Cheng Chen; Kuan-Der Lee
Journal:  Cancer       Date:  2011-12-27       Impact factor: 6.860

3.  Role of interleukin 1 beta in esophageal squamous cell carcinoma.

Authors:  Miao-Fen Chen; Ming-Shian Lu; Ping-Tsung Chen; Wen-Cheng Chen; Paul-Yang Lin; Kuan-Der Lee
Journal:  J Mol Med (Berl)       Date:  2011-09-13       Impact factor: 4.599

4.  Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.

Authors:  Leah N Cueni; Ivan Hegyi; Jay W Shin; Andrea Albinger-Hegyi; Silke Gruber; Rainer Kunstfeld; Holger Moch; Michael Detmar
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

5.  Irradiated fibroblasts promote epithelial-mesenchymal transition and HDGF expression of esophageal squamous cell carcinoma.

Authors:  Ci-Hang Bao; Xin-Tong Wang; Wei Ma; Na-Na Wang; Effat Un Nesa; Jian-Bo Wang; Cong Wang; Yi-Bin Jia; Kai Wang; Hui Tian; Yu-Feng Cheng
Journal:  Biochem Biophys Res Commun       Date:  2015-02-10       Impact factor: 3.575

6.  Tat-SmacN7 induces radiosensitization in cancer cells through the activation of caspases and induction of apoptosis.

Authors:  Fenghua Chen; Chang Xu; Liqing Du; Yan Wang; Jia Cao; Yue Fu; Yanting Guo; Qiang Liu; Feiyue Fan
Journal:  Int J Oncol       Date:  2013-01-22       Impact factor: 5.650

7.  Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy.

Authors:  N M Alajez; W Shi; A B Y Hui; S Yue; R Ng; K-W Lo; C Bastianutto; B O'Sullivan; P Gullane; F-F Liu
Journal:  Cell Death Differ       Date:  2009-07-03       Impact factor: 15.828

8.  Concordant podoplanin expression in cancer-associated fibroblasts and tumor cells is an adverse prognostic factor in esophageal squamous cell carcinoma.

Authors:  Wen-Yu Chuang; Chi-Ju Yeh; Yin-Kai Chao; Yun-Hen Liu; Yu-Sun Chang; Chen-Kan Tseng; Hsien-Kun Chang; Yung-Liang Wan; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  Combining radiation with autophagy inhibition enhances suppression of tumor growth and angiogenesis in esophageal cancer.

Authors:  Yongshun Chen; Xiaohong Li; Leiming Guo; Xiaoyuan Wu; Chunyu He; Song Zhang; Yanjing Xiao; Yuanyuan Yang; Daxuan Hao
Journal:  Mol Med Rep       Date:  2015-04-16       Impact factor: 2.952

10.  XRCC3 is a promising target to improve the radiotherapy effect of esophageal squamous cell carcinoma.

Authors:  Jingjing Cheng; Weiran Liu; Xianliang Zeng; Bin Zhang; Yihang Guo; Minghan Qiu; Chao Jiang; Huanhuan Wang; Zhiqiang Wu; Maobin Meng; Hongqing Zhuang; Lujun Zhao; Jihui Hao; Qingqing Cai; Dan Xie; Qingsong Pang; Ping Wang; Zhiyong Yuan; Dong Qian
Journal:  Cancer Sci       Date:  2015-11-06       Impact factor: 6.716

View more
  9 in total

1.  Development and verification of a hypoxia- and immune-associated prognosis signature for esophageal squamous cell carcinoma.

Authors:  Lian Lian; Shi-Bing Teng; You-You Xia; Xiao-Ming Shen; Yan Zheng; Shu-Guang Han; Wen-Jie Wang; Xue-Fei Xu; Chong Zhou
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 2.  Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.

Authors:  Joanna Kałafut; Arkadiusz Czerwonka; Alinda Anameriç; Alicja Przybyszewska-Podstawka; Julia O Misiorek; Adolfo Rivero-Müller; Matthias Nees
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

3.  NRAGE Confers Radiation Resistance in 2D and 3D Cell Culture and Poor Outcome in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Huandi Zhou; Guohui Wang; Zhiqing Xiao; Yu Yang; Zhesen Tian; Chen Gao; Xuetao Han; Wei Sun; Liubing Hou; Junling Liu; Xiaoying Xue
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

4.  Knockdown long non-coding RNA HCP5 enhances the radiosensitivity of esophageal carcinoma by modulating AKT signaling activation.

Authors:  Yue Guo; Lan Wang; Hui Yang; Nannan Ding
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

5.  CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway.

Authors:  Huixian Xin; Yuchen Liu; Pengxiang Chen; Tianwen Yin; Meijie Wang; Tianyu Liu; Zhihua Wen; Yufeng Cheng
Journal:  Discov Oncol       Date:  2022-06-29

Review 6.  Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.

Authors:  Chengpeng Sang; Dingyu Rao; Caixia Wu; Yao Xia; Maoyan Si; Zhixian Tang
Journal:  Oncol Lett       Date:  2022-07-07       Impact factor: 3.111

7.  A novel immune-related radioresistant lncRNAs signature based model for risk stratification and prognosis prediction in esophageal squamous cell carcinoma.

Authors:  Jianqing Zheng; Xiaohui Chen; Bifen Huang; Jiancheng Li
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

8.  Arbidol inhibits human esophageal squamous cell carcinoma growth in vitro and in vivo through suppressing ataxia telangiectasia and Rad3-related protein kinase.

Authors:  Ning Yang; Xuebo Lu; Yanan Jiang; Lili Zhao; Donghao Wang; Yaxing Wei; Yin Yu; Myoung Ok Kim; Kyle Vaughn Laster; Xin Li; Baoyin Yuan; Zigang Dong; Kangdong Liu
Journal:  Elife       Date:  2022-09-09       Impact factor: 8.713

9.  Overcoming radio-resistance in esophageal squamous cell carcinoma via hypermethylation of PIK3C3 promoter region mediated by KDM5B loss.

Authors:  Xiaobo Wang; Min Gu; Yongjian Ju; Juying Zhou
Journal:  J Radiat Res       Date:  2022-05-18       Impact factor: 2.438

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.